-
Product Insights
NewBone Marrow Transplant Rejection – Drugs In Development, 2024
Empower your strategies with our Bone Marrow Transplant Rejection – Drugs In Development, 2024 report and make more profitable business decisions. Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain, and shortness of breath. Treatment includes immunosuppressive drugs. The Bone Marrow Transplant...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRT-1419 in T-Cell Lymphomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PRT-1419 in T-Cell Lymphomas Drug Details: PRT-1419 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rosnilimab in Inflammation
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rosnilimab in Inflammation Drug Details: Rosnilimab (ANB-030) is under development for the treatment of graft...
-
Product Insights
NewNet Present Value Model: AnaptysBio Inc’s Imsidolimab
Empower your strategies with our Net Present Value Model: AnaptysBio Inc's Imsidolimab report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Net Present Value Model: AnaptysBio Inc’s Rosnilimab
Empower your strategies with our Net Present Value Model: AnaptysBio Inc's Rosnilimab report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Net Present Value Model: AnaptysBio Inc’s ANB-032
Empower your strategies with our Net Present Value Model: AnaptysBio Inc's ANB-032 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy to Target KK-LC-1 for Oncology in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy to Target KK-LC-1 for Oncology in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Target Kk-Lc-1 For Oncology...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pomalidomide in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pomalidomide in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Pomalidomide in Refractory Multiple Myeloma Drug Details:Pomalidomide is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ANB-032 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ANB-032 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ANB-032 in Atopic Dermatitis (Atopic Eczema)Drug Details:ANB-032 is under development for...
-
Company Insights
Innovation and Patenting activity of AnaptysBio Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of AnaptysBio Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...